Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 9/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.52 |
| ▸ | DRD2 | P14416 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13532635 | 0.88 | SIGMAR1 (0.69) | HTR1ASIGMAR1DRD2KDM4ECYP1A2 | |
| SCHEMBL13532646 | 0.87 | HTR1A (0.66) | HTR1ASIGMAR1DRD2KDM4ECYP1A2 | |
| SCHEMBL9129799 | 0.83 | CASP1 (0.62) | HTR1ASIGMAR1DRD2KDM4ECYP1A2 | |
| SCHEMBL13532645 | 0.79 | HTR1A (0.68) | HTR1ASIGMAR1DRD2KDM4ECYP1A2 | |
| SCHEMBL13532633 | 0.78 | SIGMAR1 (0.84) | HTR1ASIGMAR1DRD2KDM4ECYP1A2 | |
| SCHEMBL7486793 | 0.76 | HTR1A (0.53) | HTR1AKDM4ECYP2C9 | |
| SCHEMBL13532629 | 0.75 | SIGMAR1 (0.68) | HTR1ASIGMAR1DRD2KDM4ECYP1A2 | |
| SCHEMBL13532638 | 0.74 | HTR1A (0.88) | HTR1ASIGMAR1DRD2DRD3 | |
| SCHEMBL11981508 | 0.73 | MEN1 (0.62) | HTR1AKDM4ECYP2C9 | |
| SCHEMBL14038304 | 0.71 | HTR1A (0.76) | HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | HTR6, GAP43, HTR5A | HTR1A 7/4885SIGMAR1 201/4885DRD2 242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.